Skip to main content
. Author manuscript; available in PMC: 2010 Jul 15.
Published in final edited form as: Clin Cancer Res. 2010 Jan 12;16(2):541–553. doi: 10.1158/1078-0432.CCR-09-1960

Figure 5. Retention of the E3B-genes in the AdΔΔ mutant improved efficacy in murine immunocompetent models.

Figure 5

A) C57BL intact mice with subcutaneous TRAMPC murine prostate tumor xenografts were treated with dl309 or AdΔΔ at 1×1010 vp/injection on day 1, 3, and 5 with and without docetaxel at 15mg/kg administered intraperitoneally on day 2 and 8. Treatments were not significantly different (p>0.3). B) Representative micrographs of TRAMPC tumors stained for macrophages (CD68) and viral proteins (E1A) 15 days after intratumoral administration of one dose of the respective virus intratumorally at 1×1010vp. Magnification: 400x for CD68 and 200x for E1A. C) Survival curves for C57BL intact mice with murine colorectal CMT-93 (left panel) and lung CMT-64 (right panel) subcutaneous tumors, treated with 1×1010 vp/injection on day 1, 3, and 5 with dl922-947 (ΔE3B) (open diamond), AdΔCR2 (closed circle) and AdΔΔ (open circle) for CMT-93, and with dl922-947 and AdΔΔ for CMT-64; mock treated animals (closed square). Survival of AdΔΔ treated animals was significantly different from animals treated with dl922-947 (*p<0.02) only in the CMT-93 model, 8 animals/group.